4-(8-acetylimidazo[1,2-a]pyridin-3-yl)-2-(methylthio)pyrimidine-5-carbonitrile | 878805-79-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 4-(8-acetylimidazo[1,2-a]pyridin-3-yl)-2-(methylthio)pyrimidine-5-carbonitrile
• 英文别名: 4-(8-acetylimidazo[1,2-a]pyridin-3-yl)-2-methylsulfanylpyrimidine-5-carbonitrile
• CAS: 878805-79-9
• 化学式: C₁₅H₁₁N₅OS
• 分子量: 309.351
• InChiKey: LEDALLWQLQKRRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  109
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(8-acetylimidazo[1,2-a]pyridin-3-yl)-2-(methylthio)pyrimidine-5-carbonitrile 、 甲基溴化镁 在 水 、 氯化铵 作用下， 以 四氢呋喃 为溶剂， 生成 4-[8-(1-hydroxy-1-methylethyl)imidazo[1,2-a]pyridin-3-yl]-2-(methylthio)pyrimidine-5-carbonitrile
  参考文献：
  名称：

  EP1790650

  摘要：

  公开号：

文献信息

• Novel Substituted Imidazole Derivative
  申请人：Kawamura Mikako

  公开号：US20080070894A1

  公开（公告）日：2008-03-20

  The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X 1 , X 2 , X 3 , and X 4 , which may be identical or different, are each C or N, provided that none to two of X 1 , X 2 , X 3 , and X 4 is/are N; Y is CH or N; R 1 , R 1 ′, R 2 , R 2 ′, R 3 , R 3 ′, R 4 , and R 4 ′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R 5 is a hydrogen atom or a methyl group; R 6 and R 7 , which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R 8 and R 8 ′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R 9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.

  本发明涉及一种由式[I]表示的化合物或其药学上可接受的盐或酯：其中，X1、X2、X3和X4可以相同也可以不同，分别为C或N，但是X1、X2、X3和X4中至少有一个或最多两个是N；Y为CH或N；R1、R1'、R2、R2'、R3、R3'、R4和R4'可以相同也可以不同，分别为氢原子、低碳基或类似物；R5为氢原子或甲基基团；R6和R7可以相同也可以不同，分别为氢原子、低碳基或类似物；R8和R8'可以相同也可以不同，分别为氢原子、低碳基或类似物；R9为取代的芳基或杂环基；n为1到3的整数。本发明还涉及一种PLK1抑制剂或含有该化合物的抗癌剂。
• Substituted imidazole derivative
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US07718801B2

  公开（公告）日：2010-05-18

  The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1′, R2, R2′, R3, R3′, R4, and R4′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.

  本发明涉及一种由式[I]表示的化合物或其药学上可接受的盐或酯：其中，X1、X2、X3和X4可以相同或不同，每个为C或N，但X1、X2、X3和X4中的任意一个到两个不能是N；Y为CH或N；R1、R1'、R2、R2'、R3、R3'、R4和R4'可以相同或不同，每个为氢原子、低碳基或类似物；R5为氢原子或甲基基团；R6和R7可以相同或不同，每个为氢原子、低碳基或类似物；R8和R8'可以相同或不同，每个为氢原子、低碳基或类似物；R9为取代的芳基或杂芳基；n为1到3的整数；以及包含该化合物的PLK1抑制剂或抗癌药物。
• NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1790650A1

  公开（公告）日：2007-05-30

  The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1', R2, R2', R3, R3', R4, and R4', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.

  本发明涉及一种由式[I]代表的化合物或其药学上可接受的盐或酯： 其中 X1、X2、X3和X4（可以相同或不同）各自是C或N，条件是X1、X2、X3和X4中没有一个至两个是/是N； Y 是 CH 或 N； R1、R1'、R2、R2'、R3、R3'、R4 和 R4'（可以相同或不同）各自是氢原子、低级烷基或类似物； R5 是氢原子或甲基； R6 和 R7 可以相同或不同，各自为氢原子、低级烷基或类似物； R8 和 R8'可以相同或不同，各自为氢原子、低级烷基或类似物； R9 是芳基或杂芳基，可被取代；以及 n 是 1 至 3 的整数、 以及 PLK1 抑制剂或含有相同成分的抗癌剂。
• US7718801B2
  申请人：——

  公开号：US7718801B2

  公开（公告）日：2010-05-18